High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

Background Intratumoral injection of cyclic dinucleotide (CDN) agonists of the stimulator of interferon genes (STING) pathway engages innate immune activation and priming of adaptive immune effectors to foster local and distal tumor clearance. Despite proven therapeutic efficacy in preclinical model...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Michael A Curran, Casey R Ager, Philip Jones, Akash Boda, Kimal Rajapakshe, Spencer Thomas Lea, Maria Emilia Di Francesco, Priyamvada Jayaprakash, Ravaen B Slay, Brittany Morrow, Rishika Prasad, Meghan A Dean, Colm R Duffy, Cristian Coarfa
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2021-08-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/9/8/e003246.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!